Enrollment in Phase 2b BUOY-1 trial of GlyphAllo ™ in major depressive disorder (MDD) is on track with topline data expected in 1H 2027 Phase 1 driving simulation trial of GlyphAllo on track to report topline data in 2H 2026 Following positive data from completed Phase 1 proof-of-concept trial of
New data from Phase 1 trial of GlyphAgo TM build upon previously reported topline data and further demonstrate GlyphAgo TM can achieve therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing Enrollment in
Repeat dosing of GlyphAgo confirms favorable safety, tolerability, and pharmacokinetics observed across the Phase 1 program, with no liver-related adverse events observed New data demonstrate seven-day dosing of GlyphAgo achieved therapeutic exposures of agomelatine at doses projected to avoid
BOSTON --(BUSINESS WIRE)--Jun. 1, 2026-- Seaport Therapeutics, Inc., (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in the
BOSTON --(BUSINESS WIRE)--Apr. 30, 2026-- Seaport Therapeutics, Inc., (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing neuropsychiatric medicines, today announced the pricing of its upsized initial public offering of 14,160,000
Dr. Mates grew Intra-Cellular from discovery and early innovation through commercialization of CAPLYTA® and a $14.6 billion acquisition by Johnson & Johnson BOSTON, April 27, 2026 – Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and
GlyphAgo achieved therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing that has previously limited agomelatine’s clinical use GlyphAgo demonstrated a statistically significant 6.8-fold increase in
Newly published findings further support clinical validation of Seaport’s proprietary Glyph™ platform to enable oral dosing Data supported advancement of ongoing Phase 2b clinical trial of GlyphAllo in major depressive disorder (MDD) BOSTON, March 25, 2026 – Seaport Therapeutics (“Seaport” or
ARPA-H award supports the development of an oral prodrug using Seaport’s proprietary Glyph™ platform to address dysfunctional gut lymphatics and local inflammation linked to metabolic disease and pancreatic cancer BOSTON, March 3, 2026 – Seaport Therapeutics (“Seaport” or the “Company”), a
Meta-analysis showed an association between the frequency of clinician-administered assessments and magnitude of placebo response in generalized anxiety disorder (GAD) trials Other clinical trial design factors explored included baseline Hamilton Anxiety Rating Scale (HAM-A) score, number of trial
